Virtu Financial LLC Makes New Investment in Kura Oncology, Inc. (NASDAQ:KURA)

Virtu Financial LLC acquired a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 15,912 shares of the company’s stock, valued at approximately $139,000.

A number of other large investors have also recently made changes to their positions in KURA. Point72 DIFC Ltd purchased a new position in Kura Oncology in the 3rd quarter worth $146,000. E Fund Management Co. Ltd. purchased a new position in shares of Kura Oncology in the fourth quarter worth about $90,000. Erste Asset Management GmbH purchased a new position in shares of Kura Oncology in the third quarter worth about $215,000. Corient Private Wealth LLC acquired a new stake in shares of Kura Oncology during the fourth quarter worth about $109,000. Finally, Bellevue Group AG boosted its position in Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares during the last quarter.

Kura Oncology Price Performance

Kura Oncology stock opened at $7.05 on Monday. The stock has a market capitalization of $569.32 million, a P/E ratio of -2.99 and a beta of 0.85. The company’s fifty day moving average price is $7.82 and its 200 day moving average price is $11.94. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology, Inc. has a 1 year low of $6.79 and a 1 year high of $23.48.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million. As a group, equities research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a research note on Thursday, February 27th. Scotiabank lowered their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. StockNews.com upgraded Kura Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, March 26th. Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, UBS Group reduced their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.50.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,729 shares of company stock worth $92,307. Corporate insiders own 5.50% of the company’s stock.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.